Skip to content
OpenCapital
Get started

Metagenomi Therapeutics, Inc. MGX Q4 2024 Annual earnings

Reported March 17, 2025 · Before market open

Revenue$9.6MBeat by $382.7K
EPS-$0.63Miss by $0.01
Revenue estimate$9.2M
EPS estimate-$0.62

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$3.0M
EPS estimate-$0.55

Versus estimates

Revenue

Q1 2026$1.2MMiss by $4.7MQ4 2025$3.9MMiss by $3.4MQ3 2025$8.7MBeat by $836.4KQ2 2025$8.5MBeat by $573.0KQ1 2025$4.1MMiss by $4.2M
Q4 2024$9.6MBeat by $382.7K

Diluted EPS

Q1 2026-$0.61Miss by $0.01Q4 2025-$0.60Miss by $0.02Q3 2025-$0.55Beat by $0.05Q2 2025-$0.54Beat by $0.14Q1 2025-$0.68Miss by $0.06
Q4 2024-$0.63Miss by $0.01

Ask the moment Metagenomi Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Metagenomi Therapeutics, Inc. report Q4 2024 earnings?
Metagenomi Therapeutics, Inc. (MGX) reported Q4 2024 earnings on March 17, 2025 before market open.
What were Metagenomi Therapeutics, Inc. 's Q4 2024 revenue and EPS?
Metagenomi Therapeutics, Inc. reported revenue of $9.6M and eps of $-0.63 for Q4 2024.
Did Metagenomi Therapeutics, Inc. beat estimates in Q4 2024?
Revenue beat the consensus estimate of $9.2M by $382.7K. EPS missed the consensus estimate of $-0.62 by $0.01.
Where can I find Metagenomi Therapeutics, Inc. 's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-040217) directly on SEC EDGAR. The filing index links above go to sec.gov.